Clinical Care Options Oncology - LeukemiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4

Omacetaxine Active With Minimal Toxicity in T315I-Positive CML Patients Who Failed ImatinibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Omacetaxine resulted in durable hematologic and cytogenetic responses with an acceptable safety profile in patients with T315I-positive chronic myeloid leukemia following failure of imatinib therapy.
Source: Clinical Care Options Oncology - Leukemia - June 3, 2009 Category: Hematology Source Type: journals

High-Dose Daunorubicin Induction Improves OS in Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Increasing the dose of daunorubicin prior to transplantation provides a survival advantage without increased toxicity in younger patients with de novo AML.
Source: Clinical Care Options Oncology - Leukemia - June 2, 2009 Category: Hematology Source Type: journals

Galectin-3 Inhibitor GCS-100 Shows Single-Agent Activity in Elderly Patients With Relapsed Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - GCS-100, a galectin-3 antagonist, shows antitumor and apoptotic activity and has acceptable toxicity in elderly patients with relapsed CLL.
Source: Clinical Care Options Oncology - Leukemia - June 2, 2009 Category: Hematology Source Type: journals

Single-Agent Ofatumumab Produces Clinical Benefit in Patients With Double-Refractory or Bulky Fludarabine-Refractory CLLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Single-agent ofatumumab therapy provided a clinically significant response rates and a survival benefit among responders, according to investigators.
Source: Clinical Care Options Oncology - Leukemia - May 31, 2009 Category: Hematology Source Type: journals

Allogeneic Transplantation for Ph+ Acute Lymphoblastic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - Jacob M. Rowe, MD, FACP, explores current thinking regarding treatment strategies for adults with acute lymphoblastic leukemia.
Source: Clinical Care Options Oncology - Leukemia - April 30, 2009 Category: Hematology Source Type: journals

Allogeneic Transplantation for Ph+ Acute Lymphoblastic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download a slide presentation by Jacob M. Rowe, MD, FACP, focusing on allogeneic transplantation in patients with Philadelphia chromosome–positive ALL.
Source: Clinical Care Options Oncology - Leukemia - April 30, 2009 Category: Hematology Source Type: journals

ALL in Special Populations: Adolescents/Young Adults and Older AdultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download a presentation by Adele K. Fielding, MB BS, PhD, FRCP, FRCPath, in which she reviews treatment strategies in 2 special patient populations affected by ALL: young adults and the elderly.
Source: Clinical Care Options Oncology - Leukemia - April 23, 2009 Category: Hematology Source Type: journals

ALL in Special Populations: Adolescents/Young Adults and Older AdultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - Adele K. Fielding, MB BS, PhD, FRCP, FRCPath, reviews strategies to improve treatment outcomes in 2 special patient populations affected by ALL: young adults and the elderly.
Source: Clinical Care Options Oncology - Leukemia - April 13, 2009 Category: Hematology Source Type: journals

Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Download a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications.
Source: Clinical Care Options Oncology - Leukemia - March 11, 2009 Category: Hematology Source Type: journals

Chronic Lymphocytic Leukemia/Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Expert faculty members discuss the most important data in CLL and CML presented in San Francisco, California.
Source: Clinical Care Options Oncology - Leukemia - March 6, 2009 Category: Hematology Source Type: journals

Acute Leukemias/Myelodysplastic SyndromesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Expert Recap - Hagop M. Kantarjian, MD, provides an up-to-date analysis of the most clinically relevant new data on acute leukemias and myelodysplastic syndromes presented at the 2008 Annual Meeting of the American Society of Hematology.
Source: Clinical Care Options Oncology - Leukemia - February 26, 2009 Category: Hematology Source Type: journals

Acute Leukemias/Myelodysplastic SyndromesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Read a discussion between Hagop M. Kantarjian, MD; Alan F. List, MD; and Martin S. Tallman, MD, about the latest studies on acute leukemias and MDS presented at the ASH 2008 meeting.
Source: Clinical Care Options Oncology - Leukemia - February 5, 2009 Category: Hematology Source Type: journals

Acute Leukemias and Myelodysplastic SyndromesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download slides on the latest data on acute leukemias and myelodysplastic syndromes from the 2008 Hematology meeting.
Source: Clinical Care Options Oncology - Leukemia - January 14, 2009 Category: Hematology Source Type: journals

Hematologic MalignanciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Expert Recap - Edward Stadtmauer, MD, reviews the most important studies presented at the 2009 Clinical Oncology meeting in the settings of multiple myeloma, lymphomas, and leukemias.
Source: Clinical Care Options Oncology - Leukemia - January 7, 2009 Category: Hematology Source Type: journals

Combination of Sorafenib, Idarubicin, Cytarabine Effective in Patients Younger Than 65 Years of Age With Previously Untreated AMLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Phase I/II study show sorafenib plus idarubicin and cytarabine effective and well tolerated as frontline therapy of younger patients with AML, and that sorafenib may have in vivo inhibitory activity toward ERK and FLT3 signaling.
Source: Clinical Care Options Oncology - Leukemia - December 13, 2008 Category: Hematology Source Type: journals

Iron Overload and Transfusion-Dependence Independently Prognostic of OS and Leukemia-Free Survival in MDSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Retrospective analysis of patients with primary MDS shows development of iron overload and RBC transfusion dependency both independent prognostic factors of OS and leukemia-free survival.
Source: Clinical Care Options Oncology - Leukemia - December 13, 2008 Category: Hematology Source Type: journals

Nilotinib Induces Response in Previously Untreated Ph+ Early Chronic-Phase CMLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Nilotinib induces rapid complete cytogenetic responses and has favorable toxicity profile in early chronic-phase CML.
Source: Clinical Care Options Oncology - Leukemia - December 13, 2008 Category: Hematology Source Type: journals

STIM Study Shows CML Complete Molecular Remission Possible to Maintain Following Imatinib DiscontinuationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The probability of sustaining complete molecular remission through Month 9 was intriguingly higher among patients who received previous treatment with interferon, vs those who did not; however, the difference in this small study was not statistically significant.
Source: Clinical Care Options Oncology - Leukemia - December 13, 2008 Category: Hematology Source Type: journals

Imatinib 800 mg/day Achieves Earlier Major Molecular Response vs Imatinib 400 mg/day in Newly Diagnosed Chronic-Phase CMLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Both imatinib doses were generally well tolerated with fewer than 10% of patients discontinuing treatment in each arm.
Source: Clinical Care Options Oncology - Leukemia - December 13, 2008 Category: Hematology Source Type: journals

Cladribine, but not Fludarabine, Addition to Daunorubicin-Cytarabine Regimen Improved Survival Adults With Previously Untreated AMLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Addition of cladribine or fludarabine to standard daunorubicin-cytarabine induction therapy in a phase III study in patients with AML showed survival benefit of cladribine, but not fludarabine.
Source: Clinical Care Options Oncology - Leukemia - December 13, 2008 Category: Hematology Source Type: journals

Pomalidomide Active, Well Tolerated in Anemic Patients With MyelofibrosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Multicenter phase II trial of pomalidomide with or without prednisone in anemic patients with myelofibrosis showed increase in hemoglobin levels in 25% of patients
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Rapid, durable cytogenetic responses to dasatinib were predictive of PFS in chronic-phase CML patients who were resistant to or intolerant of imatinib therapy.
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

Addition of Rituximab to Fludarabine/Cyclophosphamide Improves PFS in Relapsed/Refractory CLL PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Rituximab plus fludarabine/cyclophosphamide produces significantly longer PFS vs fludarabine/cyclophosphamide alone in patients with relapsed/refractory CLL.
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

European Proposal for Standard Chemotherapy of Elderly Patients With Previously Untreated ALL Effective and Well ToleratedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Induction with a standard chemotherapy backbone designed for elderly patients was associated with CR in 81% of previously untreated ALL patients older than 55 years of age.
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

Romiplostim Well Tolerated in Patients Receiving Azacitidine for Low- or Intermediate-Risk MDSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Romiplostim was associated with higher platelet counts over time and decreased incidence of thrombocytopenia and platelet transfusions relative to placebo, but the differences were not significant in this small population.
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

Once-Daily Decitabine 5-Day Regimen Active and Well Tolerated in Previously Untreated Elderly Patients With Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Responses were observed in all patient subgroups, including those with poor cytogenetic risk.
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

Single-Agent Clofarabine Active and Well Tolerated in Older Adults With Untreated Acute Myelogenous Leukemia Accompanied by Unfavorable Risk FactorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Phase II trial of clofarabine in patients 60 years of age or older showed this approach safe and effective in this patient population that has poor prognostic indicators.
Source: Clinical Care Options Oncology - Leukemia - December 12, 2008 Category: Hematology Source Type: journals

Ongoing Azacitidine Treatment May Maximize Benefit in Patients With MDSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Continued azacitidine treatment following the achievement of a first response in higher-risk MDS patients resulted in an increased level of response in the AZA-001 phase III study.
Source: Clinical Care Options Oncology - Leukemia - December 11, 2008 Category: Hematology Source Type: journals

In European MDS/AML Study, Maintenance Azacitidine Treatment Feasible but Without “Clear Effect”Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Methylation of CDH and of all genes was associated with poorer survival and lower CR rate.
Source: Clinical Care Options Oncology - Leukemia - December 11, 2008 Category: Hematology Source Type: journals

Frontline Subcutaneous Low-Dose Alemtuzumab Safe and Effective in Elderly CLL Patients With 17p DeletionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Subcutaneous low-dose alemtuzumab is as effective as frontline IV administration in elderly CLL patients with the 17p chromosomal deletion
Source: Clinical Care Options Oncology - Leukemia - November 13, 2008 Category: Hematology Source Type: journals

Addition of Imatinib to Hyper-CVAD May Improve Outcomes in Patients With Ph-Positive Acute Lymphoblastic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Imatinib added to hyper-CVAD resulted in a high rate of durable remissions in patients with de novo or minimally treated Ph-positive ALL
Source: Clinical Care Options Oncology - Leukemia - October 30, 2008 Category: Hematology Source Type: journals

Novel JAK Inhibitor INCB018424 Active in Patients With Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia MyelofibrosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novel oral JAK inhibitor INCB018424 associated with substantial durable reductions in spleen size in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis
Source: Clinical Care Options Oncology - Leukemia - October 24, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Non-Hodgkins LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkins lymphoma.
Source: Clinical Care Options Oncology - Leukemia - October 20, 2008 Category: Hematology Source Type: journals

New TKI Bosutinib Active in Chronic-Phase CML Resistant to Other TKIsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novel TKI bosutinib active in patients with chronic-phase CML with imatinib intolerance or resistance, or resistance to second-generation TKIs
Source: Clinical Care Options Oncology - Leukemia - September 23, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Neil Shah, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with chronic myeloid leukemia.
Source: Clinical Care Options Oncology - Leukemia - September 19, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Non-Hodgkins LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkins lymphoma.
Source: Clinical Care Options Oncology - Leukemia - August 27, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Michael J. Keating, MB BS, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia.
Source: Clinical Care Options Oncology - Leukemia - August 13, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Myelodysplastic SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Allen S. Yang, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with myelodysplastic syndrome.
Source: Clinical Care Options Oncology - Leukemia - July 26, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Acute LeukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Farhad Ravandi, MD, discusses results presented at the 2007 hematology meeting regarding acute leukemias.
Source: Clinical Care Options Oncology - Leukemia - June 25, 2008 Category: Hematology Source Type: journals

Virtual Presentation: Multiple MyelomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amitabha Mazumder, MD, discusses new data in multiple myeloma presented at the 2007 hematology meeting.
Source: Clinical Care Options Oncology - Leukemia - May 30, 2008 Category: Hematology Source Type: journals

Management of a 69-Year-Old Patient With Deletion 5q Myelodysplastic SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Alan F. List, MD, reviews treatment options for a patient with del(5q) MDS.
Source: Clinical Care Options Oncology - Leukemia - May 12, 2008 Category: Hematology Source Type: journals

Clinical Management of a 69-Year-Old Man With Intermediate-1-Risk Myelodysplastic SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this Interactive Case Challenge, Azra Raza, MD, and Naomi Galili, PhD, discuss treatment options for a patient with intermediate-risk myelodysplastic syndrome and monosomy of chromosome 7.
Source: Clinical Care Options Oncology - Leukemia - April 24, 2008 Category: Hematology Source Type: journals

Slideset Module: Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Download a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications.
Source: Clinical Care Options Oncology - Leukemia - April 22, 2008 Category: Hematology Source Type: journals

Expert Analysis: Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Moshe Talpaz, MD; Brian Druker, MD; Charles L. Sawyers, MD; and Allen Yang, MD, PhD, review clinical data on chronic myeloid leukemia presented at the 2007 hematology meeting.
Source: Clinical Care Options Oncology - Leukemia - April 12, 2008 Category: Hematology Source Type: journals

Expert Recap: Chronic Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Watch and listen as Moshe Talpaz, MD, reviews the latest data on chronic myeloid leukemia treatment presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia.
Source: Clinical Care Options Oncology - Leukemia - April 11, 2008 Category: Hematology Source Type: journals

Expert Recap: Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this Expert Recap, Michael J. Keating, MB BS, reviews the most up-to-date data on chronic lymphocytic leukemia presented at the 2007 annual hematology meeting in Atlanta, Georgia.
Source: Clinical Care Options Oncology - Leukemia - April 3, 2008 Category: Hematology Source Type: journals

Expert Analysis: Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
John C. Byrd, MD, Michael J. Keating, MB BS, and Kanti Rai, MD, discuss the latest clinical data on treatment of chronic lymphocytic leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Roy A. Beveridge, MD.
Source: Clinical Care Options Oncology - Leukemia - March 27, 2008 Category: Hematology Source Type: journals

Expert Analysis: Acute LeukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hagop M. Kantarjian, MD; Dan Douer, MD; and Stephen J. Forman, MD, discuss the latest clinical data on treatment of acute leukemias presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Mark Kirschbaum, MD.
Source: Clinical Care Options Oncology - Leukemia - March 19, 2008 Category: Hematology Source Type: journals

Expert Analysis: Myelodysplastic SyndromesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Read a discussion among Alan F. List, MD; Lewis R. Silverman, MD; and Azra Raza, MD, and moderated by Allan S. Yang, MD, PhD, on the key studies presented at ASH 2007 regarding treatment and pathogenesis of myelodysplastic syndromes.
Source: Clinical Care Options Oncology - Leukemia - March 14, 2008 Category: Hematology Source Type: journals

Pretransplant Imatinib During First Chronic Phase Associated With Improved Survival in CMLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Patients with CML in first chronic phase treated with imatinib prior to HSCT have improved survival vs patients who do not receive imatinib
Source: Clinical Care Options Oncology - Leukemia - March 13, 2008 Category: Hematology Source Type: journals